EGFR and metastatic neoplasm: Features at the bottom of the plot, such as underweight pretreatment BMI, EGFR status, pre-existing metastatic disease, and immunotherapy with anti-PD-1 plus chemotherapy, showed minimal impact on the model’s predictions, as evidenced by their SHAP values nearing zero.